“Yon has been a valuable contributor and member of the Cancer Center for many years, and we welcome the opportunity to have him join our leadership ranks to continue the growth and trajectory of our center,” Scot Remick, M.D., director of WVU’s Cancer Center, said.
As co-leader of the Allen Lung Cancer Program, Dr. Rojanasakul will work with the leadership team and the program participants to advance lung cancer research and patient care capabilities.
“This is a great honor, and I am excited to be part of the Cancer Center leadership team and to lead the Allen Lung Cancer program,” Rojanasakul said. “The Mary Babb Randolph Cancer Center has grown tremendously in the past few years, and I am pleased to be part of this transition. I look forward to expanding our research collaborations to include other investigators in related fields and in other cancer programs.”
Research in the Allen Lung Cancer Program focuses on the prevention and treatment of lung cancer. “Our research team will work on identifying cancer risks, disease mechanisms and novel and more effective ways of treating lung cancer,” Rojanasakul said.
Rojanasakul’s research includes a $1.4-million grant from the National Heart, Lung and Blood Institute of the National Institutes of Health to determine if engineered nanomaterials, such as carbon nanotubes, may be linked to lung cancer.
Rojanasakul is a professor in the WVU School of Pharmacy’s Department of Basic Pharmaceutical Sciences. He also is a faculty member of the Molecular Mechanisms of EMT (epithelial-to-mesenchymal transition) and Metastasis Program at the Cancer Center.
For more information: Amy Johns, HSC News Service, 304-293-7087